ATAI Life Sciences NV (ATAI) Actualités

Form 8-K - Current report

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01...

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...

Form 8-K - Current report

Form 8-K - Current report

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in...

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)

VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of...

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...